American Thyroid Association

Viridian Therapeutics Announces Presentations at Multiple Medical Meetings in September

Retrieved on: 
Thursday, September 7, 2023
Health, General Health, Research, Science, Pharmaceutical, Optical, Biotechnology, Abstract, American Thyroid Association, ATA, Graves' ophthalmopathy, DC, ETA, Annual general meeting, European Society of Clinical Microbiology and Infectious Diseases, Pharmacology, Therapy, TED, Pharmaceutical industry, Vaccine, Patient

Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced that multiple abstracts featuring clinical and preclinical data on the Company’s pipeline candidates for the treatment of thyroid eye disease (TED) will be presented at the following medical meetings:

Key Points: 
  • Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced that multiple abstracts featuring clinical and preclinical data on the Company’s pipeline candidates for the treatment of thyroid eye disease (TED) will be presented at the following medical meetings:
    The 45th Annual Meeting of the European Thyroid Association (ETA) to be held September 9-12, 2023, in Milan, Italy
    The 41st Annual Meeting of the European Society of Ophthalmic Plastic and Reconstructive Surgery (ESOPRS) to be held September 14-16, 2023, in Naples, Italy
    The Annual Meeting of the American Thyroid Association (ATA) to be held September 27-October 1, 2023, in Washington, DC
    Presentations at all three conferences will highlight clinical and pharmacologic data from studies of VRDN-001, a full antagonist antibody to the insulin-like growth factor-1 receptor (IGF-1R), in development for TED.
  • An additional presentation will feature pharmacokinetic data for VRDN-003, a next-generation, half-life extended antibody to IGF-1R for TED.
  • The Company will also present clinical pharmacodynamic responses to VRDN-001 in healthy volunteers and patients with active TED.
  • VRDN-001, a Full Antagonist Antibody to IGF-1 Receptor: In Vitro Pharmacology and Phase 1/2 Results in Patients with Thyroid Eye Disease
    Preclinical Pharmacokinetics and Clinical Exposure Prediction for VRDN-003, a Next-Generation Half-life Extended Antibody to IGF-1R for Thyroid Eye Disease
    In Vitro Pharmacology and Phase 1/2 Results of VRDN-001, a Full Antagonist Antibody to IGF-1 Receptor for Thyroid Eye Disease

World-Renowned Scientist and Researcher Yaron Tomer, MD, named the Marilyn and Stanley M. Katz Dean at Einstein

Retrieved on: 
Friday, September 8, 2023
Diversity, equity, and inclusion, Albert Einstein, American Thyroid Association, Doctor of Education, College, Education, Icahn School of Medicine at Mount Sinai, The College of Medicine, Blue Ridge, COVID-19, Department of Medicine – University of Pamplona, Marilyn, Mount Sinai, Doctor of Philosophy, Associate, Science, Molecular medicine, Student, Social justice, Professor, MD, Division, Physician, Anita, Sheba Medical Center, Faculty, DEI, Growth, Albert Einstein College of Medicine, Environment, NIH, Social medicine, Nursing, Management, Montefiore, Endocrinology, Research

BRONX, N.Y., Sept. 8, 2023 /PRNewswire/ -- Yaron Tomer, MD, has been named the Marilyn and Stanley M. Katz Dean at the Albert Einstein College of Medicine , effective October 2nd, 2023.

Key Points: 
  • BRONX, N.Y., Sept. 8, 2023 /PRNewswire/ -- Yaron Tomer, MD, has been named the Marilyn and Stanley M. Katz Dean at the Albert Einstein College of Medicine , effective October 2nd, 2023.
  • As Dean, Dr. Tomer will lead this research-intensive medical school comprised of more than 1,900 full-time faculty to further advance its research, education, diversity, community engagement, and philanthropic missions.
  • Dr. Tomer will ensure Einstein continues its national leadership in biomedical research support, while offering one of the nation's largest programs for medical education.
  • His leadership will foster an environment that will prepare students and faculty to make lasting contributions to science."

My scan shows I have thyroid nodules. Should I be worried?

Retrieved on: 
Wednesday, April 26, 2023
People, Thyroid nodule, Review, Low, Thyroid hormones, Pressure, American Thyroid Association, CT, Thyroid, Radiation, Radiation exposure, Obesity, Neck pain, Anxiety, Cancer, Woman, Medicine, Overdiagnosis, Cell, Neck, Catherine Disher, Incidence, Man, Population, Patient, Lymph, Risk, Time, Diagnosis, Ageing, System, Health, Thyroid cancer, Copper, Legume, Pharmaceutical industry, Medical imaging, Mobile phone

A thyroid nodule is a solid or fluid-filled lump found within the thyroid.

Key Points: 
  • A thyroid nodule is a solid or fluid-filled lump found within the thyroid.
  • The majority of thyroid nodules are small, can’t be felt by touch and do not cause symptoms.
  • Thyroid nodules are very common, with more than half of people scanned show small nodules.

Who gets them

    • At age 30 it is estimated around 30% of women will have a nodule.
    • People often find out that they have thyroid nodules during a routine check-up or when investigating another unrelated health issue.
    • Thyroid nodules are readily seen on common imaging tests such as an ultrasound or CT scans.

When should you worry?

    • But we now know around 10% of patients with thyroid nodules harbour cancer – so approximately 90% of those detected don’t pose a cancer risk.
    • Generally, the risk is only increased with past radiation exposure, a family history of thyroid cancer, obesity, or if aged younger than 20 at the time of discovery of the nodule.
    • Symptoms of concern are: an enlarging thyroid nodule, recent onset of hoarseness, difficult swallowing, neck pain or discomfort, large firm nodule or surrounding enlarged lymph nodes.

When detection leads to poorer health

    • In recent decades, the dramatic increase in new cases of thyroid cancer has largely been driven by findings of small, low-risk thyroid cancers; found when investigating thyroid nodules.
    • Strong evidence exists overdiagnosis – that is, a correct but unnecessary diagnosis – accounts for a large proportion of thyroid cancer cases.
    • In line with this, systems for ultrasound reporting have been introduced to reduce overtreatment of small thyroid nodules.
    • Read more:
      Low- and middle-income countries struggle to provide health care to some, while others get too much medicine

Take-home advice

    • Investigating and treating these nodules can lead to unwarranted physical, psychological and financial consequences including overdiagnosis, overtreatment, anxiety and out-of-pocket costs.
    • Patti Shih's research projects are funded by the National Health and Medical Research Council (NHMRC)

New Guidelines Cite Oral Levothyroxine Solution as an Option for Treating Congenital Hypothyroidism (CH)

Retrieved on: 
Thursday, January 12, 2023
Cincinnati Children's Hospital Medical Center, Congenital hypothyroidism, Hypothyroidism, University, University of Cincinnati, Pediatrics (journal), Caregiver, American Academy of Pediatrics, Medicine, ATA, Safety, PES, FDA, American Thyroid Association, Craniosynostosis, Water, Mouth, CH, Patient, Thyroid hormones, Lactose, American Academy, Journal, Hormone Research in Paediatrics, IBSA, Glycerol, AAP, Birth defect, Pharmaceutical industry, Pediatrics

PARSIPPANY, N.J., Jan. 12, 2023 /PRNewswire/ -- The American Academy of Pediatrics (AAP), the Pediatric Endocrine Society (PES) and the American Thyroid Association (ATA) have published new guidelines for the treatment of congenital hypothyroidism (CH). For the first time, these leading medical societies cite levothyroxine oral solution as an option for managing patients with CH. Congenital hypothyroidism is a condition affecting up to 1 in every 2,000-4,000 live births in the United States annually. It is a leading cause of intellectual deficiency among infants.1 CH is typically treated with levothyroxine, a synthetic thyroid hormone that is administered daily to restore thyroid hormones to normal levels. Tirosint-SOL (levothyroxine sodium) oral solution is the leading FDA-approved levothyroxine oral solution currently available in the US.

Key Points: 
  • For the first time, these leading medical societies cite levothyroxine oral solution as an option for managing patients with CH.
  • Tirosint-SOL (levothyroxine sodium) oral solution is the leading FDA-approved levothyroxine oral solution currently available in the US.
  • A randomized clinical study published in the journal Hormone Research in Pediatrics examined the efficacy and safety of treating infants newly diagnosed with CH with levothyroxine oral solution in lieu of traditional levothyroxine tablet formulations.
  • In total, 78 infants with congenital hypothyroidism (CH) were studied.2 The study's authors concluded that levothyroxine oral solution was able to successfully treat CH patients to their therapeutic goals.

Data Published in JCEM Demonstrate Strong Real-World Performance of Veracyte’s Afirma GSC in Thyroid Cancer Diagnosis

Retrieved on: 
Thursday, December 15, 2022
Technology, Genetics, Clinical Trials, Health Technology, Software, Biotechnology, General Health, Pharmaceutical, Health, Oncology, NanoString Technologies, Laboratory, JCEM, Physician, Malignancy, ITN, American Thyroid Association, Research, Diagnosis, Thyroid nodule, Health, Patient, Biopsy, Arizona College of Osteopathic Medicine, Meta-analysis, The Journal of Clinical Endocrinology and Metabolism, Annual report, Thyroid cancer, FDA, CLIA, Journal, CV, FNA, University, BCR, GSC, Metabolism, University of Arizona College of Medicine – Tucson, RNA, Risk, Pharmaceutical industry, Medical device, Medical imaging, Endocrinology

Veracyte, Inc. (Nasdaq: VCYT) today announced that findings demonstrating the strong real-world performance of the Afirma Genomic Sequencing Classifier (GSC) were published in The Journal of Clinical Endocrinology & Metabolism (JCEM) .

Key Points: 
  • Veracyte, Inc. (Nasdaq: VCYT) today announced that findings demonstrating the strong real-world performance of the Afirma Genomic Sequencing Classifier (GSC) were published in The Journal of Clinical Endocrinology & Metabolism (JCEM) .
  • Our analysis found that the test performs just as well and on some measures better in clinical practice.
  • This is incredibly encouraging and reassuring for physicians who must determine the best clinical approach for patients with indeterminate thyroid nodules.
  • The Afirma Genomic Sequencing Classifier helps physicians identify patients with benign thyroid nodules among those with indeterminate FNA results, so that they may avoid unnecessary thyroid surgery.

Viridian Presents Positive Clinical Data from Ongoing VRDN-001 Phase 1/2 Trial in Active Thyroid Eye Disease (TED) Patients During Late-Breaking Presentations at the American Thyroid Association (ATA) 91st Annual Meeting

Retrieved on: 
Saturday, October 22, 2022
U.S. Securities and Exchange Commission, Teprotumumab, Orbit, Plasma, Cedars-Sinai Medical Center, SEC, Therapy, Diplopia, CAS, NASDAQ, Patient, Research, Security (finance), Annual general meeting, Severe cognitive impairment, Inflammation, American Thyroid Association, Eye, Private Securities Litigation Reform Act, ATA, Orbital, Hyperglycemia, Șaeș, Company, Pain, Safety, GLOBE, Fibrosis, Forward-looking statement, Graves' ophthalmopathy, Disclosure, Half-life, Huber loss, Copper, Pharmaceutical industry, Generic drug, TED, Poster, Viridian

WALTHAM, Mass., Oct. 22, 2022 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company advancing new treatments for patients suffering from serious diseases underserved by current therapies, presented positive proof-of-concept data from the 10 mg/kg cohort in its ongoing Phase 1/2 clinical trial of VRDN-001, an anti-IGF-1R antibody, in patients with active thyroid eye disease (TED). These data, as well as new in vitro data further characterizing and differentiating the pharmacological profile of VRDN-001, were included as part of three late-breaking poster presentations at the American Thyroid Association (ATA) 91st Annual Meeting. The abstract describing new in vitro data on the distinct anti-IGF-1R profile of VRDN-001 was also selected as an oral highlighted late breaking presentation. The three posters are available on the Viridian website (click here).

Key Points: 
  • Poster #535 presents proof-of-concept data from the first cohort of patients with active TED treated in the ongoing Phase 1/2 clinical trial.
  • In patients receiving VRDN-001, proptosis response was achieved by 83% of patients, with a mean reduction of 2.4 mm from baseline.
  • Clinical Activity Score (CAS) of 0 or 1 was achieved by 83% of patients, with a mean reduction of 4.3 points from baseline.
  • Poster #568 presents full safety and pharmacodynamic data from the completed healthy volunteer portion of the ongoing Phase 1/2 trial of VRDN-001.

Interpace Biosciences Announces New Real-world Data; Presented at the American Thyroid Association 2022 Annual Meeting

Retrieved on: 
Thursday, October 20, 2022
Physician, MicroRNA, U.S. Securities and Exchange Commission, Pancreatic cancer, Personal Data Privacy and Security Act of 2009, COVID19, Risk, BCR, Broad, Review, Natural borrowing limit, Diagnosis, Pancreatic cyst, LLC, Sumathi Best Television Current Reporting Award, Securities Exchange Act of 1934, Patient, Poster, CMS, Security (finance), Cancer, Esophageal cancer, Securities Act of 1933, American Thyroid Association, CEP, Technology, Private Securities Litigation Reform Act, ATA, Lung cancer, Mirna, Company, Doctor of Philosophy, Thyroid cancer, CEO, Safety, Prognosis, Franciscan Ceramics, GLOBE, EBITDA, Comerica, ITN, Terminology, Annual general meeting, Medical imaging, Pharmaceutical industry, Medical device

The findings are from an independent study and were shared today in a highlighted poster presentation during the American Thyroid Association (ATA) 2022 Annual Meeting (Poster #119).

Key Points: 
  • The findings are from an independent study and were shared today in a highlighted poster presentation during the American Thyroid Association (ATA) 2022 Annual Meeting (Poster #119).
  • A secondary, retrospective analysis was also performed with ThyraMIRv2, the Companys new miRNA pairwise expression profiler.
  • Additionally, a blinded analysis of pairwise miRNA expression profiling demonstrated improved accuracy from the original testing platform.
  • Because of these and other risks, uncertainties, and assumptions, undue reliance should not be placed on these forward-looking statements.

Horizon Therapeutics plc to Present New Data on TEPEZZA® (teprotumumab-trbw) and Thyroid Eye Disease (TED) at the American Thyroid Association (ATA) Annual Meeting

Retrieved on: 
Thursday, October 13, 2022
Biotechnology, Pharmaceutical, Optical, General Health, Health, FDA, Clinical Trials, Other Health, Pressure, Physician, LinkedIn, Spasm, Fibroblast, Breathe Me, Disease, Medicine, Diabetes, Nausea, Fatigue, Menstrual disorder, Graves' ophthalmopathy, Science, TED, Inflammatory bowel disease, Myalgia, FACP, Patient, Diarrhea, Courage, Tachycardia, Research, Twitter, Instagram, Cell, Blood pressure, Severe cognitive impairment, Hair, Nasdaq, Red, Grit, Hyperglycemia, Autoantibody, ATA, Headache, Swelling, Pain, Incidence, IBD, European Group, Lists of World Heritage Sites, Autoimmunity, Inflammation, Health, FDA, Exophthalmos, Huber loss, American Thyroid Association, Pharmaceutical industry, Vaccine, Medical device, Medical imaging, Birth control, Facebook, Dysgeusia

Horizon Therapeutics plc (Nasdaq: HZNP) today announced new data will be presented at the 91st Annual Meeting of the American Thyroid Association ( ATA 2022 ) in Montreal, October 19-23.

Key Points: 
  • Horizon Therapeutics plc (Nasdaq: HZNP) today announced new data will be presented at the 91st Annual Meeting of the American Thyroid Association ( ATA 2022 ) in Montreal, October 19-23.
  • We look forward to bringing these important data to the forefront to help physicians better understand the condition for their patients.
  • Infusion reactions have been reported in approximately 4% of patients treated with TEPEZZA.
  • Preexisting Inflammatory Bowel Disease: TEPEZZA may cause an exacerbation of preexisting inflammatory bowel disease (IBD).

New Data Show Strong Performance of Veracyte’s Afirma GSC in Real-World Clinical Practice

Retrieved on: 
Monday, June 20, 2022
Biotechnology, Health Technology, Genetics, Health, ENDO, Time, Laboratory, Cancer, LDT, FDA, Investor, Form 10-Q, Annual report, Malignancy, Thyroid cancer, Forward-looking statement, Meta-analysis, American Thyroid Association, FNA, SEC, CV, GSC, Biopsy, Twitter, Incidence, Patient, Endocrinology, Health, Diagnosis, Conference, Annual conferences, Risk, Pharmaceutical industry, Medical device

The Afirma GSCs clinical validation study provided high-quality evidence of our tests ability to rule out malignancy in indeterminate thyroid nodules to help these patients avoid unnecessary surgery.

Key Points: 
  • The Afirma GSCs clinical validation study provided high-quality evidence of our tests ability to rule out malignancy in indeterminate thyroid nodules to help these patients avoid unnecessary surgery.
  • An example of a forward-looking statement includes, among others, that the Afirma GSC can improve thyroid cancer diagnosis in patients with indeterminate thyroid nodules.
  • The Afirma GSC is available as part of Veracytes CLIA-validated laboratory developed test (LDT) service.
  • Veracyte, the Veracyte logo and Afirma are registered trademarks of Veracyte, Inc. and its subsidiaries in the U.S. and selected countries.

Global Endocrine Testing Market Analysis/Research Report 2022-2027: Tests to Measure Thyroid-Stimulating Hormone (TSH) are Expected to Influence Market Growth - ResearchAndMarkets.com

Retrieved on: 
Thursday, April 28, 2022
Health, Biotechnology, First Nations in Ontario, Triiodothyronine, Androgen deficiency, FT4, Thyroid disease, COVID-19, Roche, University Medical Center Groningen, Thyroid, Department, Geriatrics, ATA, American Thyroid Association, FT3, Incidence, Patient, UN, Tobacco, Growth, Risk, Laboratory, Abbott Laboratories, TT3, Growth hormone, Woman, Smoking, Groningen, CAGR, United Nations, Technology, Serum, Research, University of Groningen, Nephrology, Hypothyroidism, TSH, Menopause, University, Hyperthyroidism, Government, Disease, Endocrine system, Man, Medical device, Vaccine, Pharmaceutical industry, Agriculture

Globally, hormonal imbalances are increasing among individuals of all ages, which is driving the endocrine testing market.

Key Points: 
  • Globally, hormonal imbalances are increasing among individuals of all ages, which is driving the endocrine testing market.
  • Since endocrine testing tools are in high demand, market players are more committed to developing new products.
  • The demand for advanced endocrine testing technologies is also expected to grow due to diseases such as hypothyroidism and hyperthyroidism.
  • As a result, the rise in TSH testing is expected to boost market growth for the global endocrine testing market.